Wijeyanthy Wijeyakumar, Thomas Hong,Geoffrey K Broadhead, Haitao Li, Meidong Zhu,Andrew A Chang
To assess the impact of intravitrealAflibercept on vision-related quality of life (VR-QoL)in patients with refractory neovascular age-relatedmacular degeneration (nAMD) over 6 months.
49 patients with refractory nAMD whowere previously treated with anti-vascular growthfactor therapy were treated with Aflibercept as part ofa prospective study over 6 months. Full ophthalmicexamination including best corrected visual acuity(BCVA), central macular thickness (CMT) assessed byspectral domain optical coherence tomography (SD-OCT), and VR-QoL measured with the National EyeInstitute Visual Functioning Questionnaire-25 (NEIVFQ- 25) were performed at baseline and 6 months.VR-QoL subscales assessed a range of vision functionincluding near and distance activities, mental health,driving, and social functioning. Change in NEI VFQ-25scores and correlations with BCVA and CMT wereanalysed.
BCVA improved and CMT was reduced sig-nificantly with a mean improvement of 6.9 letters anda decrease of 89.4 ?m in CMT at 6 month (p < 0.001).Overall NEI-VFQ25 composite scores improved at 6months compared to baseline (73.45 versus 70.25,p = 0.004). All subscales except for general healthshowed an improvement after 6 months. Social func-tioning, mental health, near and distance activities allshowed a significant improvement (p < 0.05). No cor-relations were observed between changes in NEI VFQ-25 and changes in BCVA or CMT.
Overall vision-related quality of lifeimproved following Aflibercept treatment over 6months compared to baseline; however this did notcorrelate with changes in BCVA or CMT.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY